<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00900588</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-sPanFlu-2001</org_study_id>
    <nct_id>NCT00900588</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Adolescents</brief_title>
  <official_title>Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Adolescent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinovac Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Disease Control and Prevention, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sinovac Biotech Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single center, stratified, randomized and double-blind phase II clinical trial was
      conducted in adolescents to evaluate the safety and immunogenicity of a split-virion pandemic
      influenza A vaccine (H5N1).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HI antibody and Neutralization antibody</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions</measure>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>10 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 microgram split-virion vaccine per dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 microgram split-virion vaccine per dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 microgram split-virion vaccine per dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 ug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 microgram whole-virion vaccine per dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)</intervention_name>
    <arm_group_label>10 ug</arm_group_label>
    <arm_group_label>15 ug</arm_group_label>
    <arm_group_label>30 ug</arm_group_label>
    <arm_group_label>5 ug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adolescent aged 12-17 years old

          -  Be able to show legal identity card for the sake of recruitment

          -  Volunteers or their parents are able to understand and sign the informed consent

          -  Do not participate in other clinical trial

        Exclusion Criteria:

          -  Any history of allergic reactions

          -  Autoimmune disease or immunodeficiency

          -  Asthma that is unstable or required emergent care, hospitalization or intubation
             during the past two years or that required the use of oral or intravenous
             corticosteroids

          -  Diabetes mellitus (type I or II), with the exception of gestational diabetes

          -  History of thyroidectomy or thyroid disease that required medication within the past
             12 months

          -  Serious angioedema episodes within the previous 3 years or requiring medication in the
             previous two years

          -  Hypertension that was not well controlled by medication or the blood pressure is more
             than 145/95 mmHg at enrollment

          -  Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or
             platelet disorder requiring special precautions) or significant bruising or bleeding
             difficulties with IM injections or blood draws

          -  Active malignancy or treated malignancy for which there is not reasonable assurance of
             sustained cure or malignancy that is likely to recur during the period of study

          -  Seizure disorder other than:

               1. Febrile seizures under the age of two years old

               2. Seizures secondary to alcohol withdrawal more than 3 years ago, or

               3. A singular seizure not requiring treatment within the last 3 years

          -  Asplenia, functional asplenia or any condition resulting in the absence or removal o
             the spleen

          -  Guillain-Barre Syndrome

          -  Any history of immunosuppressive medications or cytotoxic medications or inhaled
             corticosteroids within the past six months (with the exception of corticosteroid nasal
             spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated
             dermatitis)

          -  History of any blood products administration within 3 months before the dosing

          -  Administration of any other investigational research agents within 30 days before the
             dosing

          -  Administration of any live attenuated vaccine within 30 days before the dosing

          -  Administration of subunit or inactivated vaccines, e.g., pneumococcal vaccine, or
             allergy treatment with antigen injections, within 14 days before the dosing

          -  Be receiving anti-TB prophylaxis or therapy currently

          -  Axillary temperature &gt; 37.0 centigrade at the time of dosing

          -  Psychiatric condition that precludes compliance with the protocol:

               1. Past or present psychoses

               2. Past or present bipolar disorder requiring therapy that has not been well
                  controlled on medication for the past two years

               3. Disorder requiring lithium

               4. Suicidal ideation occurring within five years prior to enrollment

          -  Any medical, psychiatric, social condition, occupational reason or other
             responsibility that, in the judgment of the investigator, is a contraindication to
             protocol participation or impairs a volunteer's ability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Centers for Diseases Control and Prevention</name>
      <address>
        <city>Beijing</city>
        <zip>100013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2009</study_first_submitted>
  <study_first_submitted_qc>May 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2009</study_first_posted>
  <last_update_submitted>August 10, 2009</last_update_submitted>
  <last_update_submitted_qc>August 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2009</last_update_posted>
  <keyword>immunogenictiy</keyword>
  <keyword>safety</keyword>
  <keyword>pandemic influenza A vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

